Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current Assets    
Cash and cash equivalents $ 17,116 $ 19,055
Prepaid expenses and other current assets 827 2,515
Total Current Assets 17,943 21,570
Property and equipment, net 872 905
Deposits and other assets 23 23
Total Assets 18,838 22,498
Current Liabilities:    
Accounts payable 2,020 1,993
Accrued expenses 1,526 2,627
Warrant liabilities 4,083 14,821
Accrued employee benefits 2,074 313
Deferred rent 90 3
Total Current Liabilities 9,793 19,757
Long term deferred rent 402 492
Total Liabilities 10,195 20,249
Stockholders’ (Deficit) Equity:    
Common stock, $0.001 par value; 350,000,000 shares authorized, 128,648,365 issued and 128,566,886 outstanding and 117,254,196 issued and 117,172,714 outstanding 129 117
Additional paid-in capital 192,545 175,762
Accumulated deficit (194,170) (172,034)
Total Synthetic Biologics, Inc. and Subsidiaries (Deficit) Equity (1,496) 3,845
Non-controlling interest (1,914) (1,596)
Total Stockholders’ (Deficit) Equity (3,410) 2,249
Total Liabilities and Stockholders’ (Deficit) Equity 18,838 22,498
Series A Preferred Stock [Member]    
Current Liabilities:    
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized; 120,000 and zero shares issued and outstanding $ 12,053 $ 0